Clinical Drug Investigation

, Volume 28, Issue 11, pp 673–686 | Cite as

Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk Factors

An Open-Label, Observational, Multicentre, General Practice-Based Study
  • Richard Ian Ogilvie
  • Sanjiv Anand
  • Pierre Roy
  • Selwyn De Souza
Original Research Article

Abstract

Background and objectives: Hypertension, one of the major treatable cardiovascular (CV) risk factors, usually occurs in association with other major risk factors. As well as providing rapid blood pressure (BP) goal attainment, antihypertensive therapy should also provide reductions in CV events and mortality in a wide range of patients. For this, higher dosages and combinations of antihypertensive agents are often required. ACE inhibitors are recommended as first-line agents for control of hypertension in patients with additional CV risk factors. The PEACH (Perindopril’s Effect At Controlling Hypertension) study was a community-based study performed to evaluate the effectiveness and safety of highdose perindopril in patients with mild-to-moderate hypertension and additional risk factors for CV disease.

Methods: This was an open-label, multicentre observational study conducted in Canadian general practice clinics. The study assessed the efficacy and tolerability of perindopril given once daily for 10 weeks uptitrated to the maximal recommended dose of perindopril as required for BP control in newly diagnosed or previously treated patients with uncontrolled mild to moderate hypertension and ≥1 additional risk factor. Patients not achieving target BP after 2 weeks of therapy were uptitrated from perindopril 4 mg to perindopril 8 mg once daily. Efficacy endpoints included reduction in systolic (SBP) and diastolic (DBP) BP and BP control. Tolerability assessments included adverse effects and physicians’ assessment of tolerability. The number of missed doses was also recorded.

Results: Overall, 2220 patients with hypertension and ≥1 other risk factor were prescribed perindopril at 291 centres; 51.9% were male, 78.3% Caucasian, 12.8% Asian, 36.2% ≥65 years of age and 34.5% had uncontrolled BP despite previous antihypertensive treatment. Compared with previously treated patients, treatment-naive patients had fewer risk factors, and a higher proportion were Asian (p < 0.05 for all comparisons). Most patients (76%) had 1–2 risk factors. Perindopril produced significant SBP/DBP reductions at 2 and 10 weeks (−15.8/−8.0 and −21.1/−11.0 mmHg, respectively). Overall, at week 10, BP control rate was 53.6%, better than at week 2 in the overall cohort and in all subgroups. Uptitration to high-dose perindopril to achieve BP control was required in 46% of patients with one additional risk factor compared with 64% of patients with ≥4 additional risk factors. These results demonstrate that the more risk factors the patient has, the greater the need for high-dose perindopril to achieve BP control. Perindopril was well tolerated as indicated by the high proportion of physicians (95.9%) reporting ‘good’ to ‘excellent’ tolerability at week 10.

Conclusion: In this community-based clinical practice trial, up to 10 weeks’ perindopril therapy, uptitrated to the maximal recommended dose as required for BP control, significantly reduced SBP/DBP in patients with mild-to-moderate hypertension and additional CV risk factors. Patients with more risk factors were more likely to require high-dose perindopril.

Notes

Acknowledgements

This study was supported by an unrestricted educational grant from Servier. The manuscript was prepared with medical writing assistance from Mary Hines, Vicki Oldfield and Joanne Dalton of Wolters Kluwer Health.

Dr Ogilvie has received honoraria from Servier for participation in workshops and lectures supported by grants from Servier and for his consultative role in the design, analysis and preparation of this manuscript describing the PEACH study and its findings. Dr Anand has received honoraria from Servier for facilitation of continuing medical education events and for his role as coordinator of the PEACH study. The other authors have no financial interests or conflicts of interest that are directly relevant to this study.

PEACH study investigators: E. Schwartz, G. Brouillette, M. Krisdaphongs, C. Riche, S. Ko, M. Leung Sui Fung, G. Barrière, N. Khotianov. L. Kohut, A. Lam, J. Casserly, A. Kopyto, F. Urfer, R. Zarruk, P. Zubkov, M. Faizer, S. Devi, B. Dick, E. Inandan, I. Roitberg, D. Wong, J. Desroches, A. Ahmad, D. Beytell, G. Gatesman, E.J. Pauls, T. Lotfallah, D.E. Hunsberger, M. Ho-Asjoe, K.G. Sie, T. Subramanian, A.W. Carter, J. Goncalves, C. Che, R. Jato-Rodriguez, L. Shimanovsky, D. Yim, A. Razzaque, P. Mehta, K. Bienkowski, Q. Truong, H. William, R. Ciomyk, A. Stern, B.H. Trinh, F. Papadopoulos, S. Rodriguez, P.K Pang, M.L. Van Rooyen, S. Dion, G. Huculak, D.R. Spink, R. Lindzon, D. Norris, S.J. Scala, A.P. Vandenberg, M. Veall, J-M. Martel, I. Lombard, M. Kazimirski, G. Rideout, M.H.M. Tran, V. Martinho, R. Lam, M.S. Parikh, R. Rose, C. Lang, B. Roy, E. Weatherston, P. Wong, D. Lafortune, K. Cho, A. Trevor, N.C. Krayacich, K. Moran De Muller, A. Nayar, J. Morin, C. Guite, P. Diaz, T. Magennis, J.K. Chan, R. Collette, E. Bellavance, C. Nolan, H. Wrobel, A. Trenholm, A. Kuchtaruk, G.S. Meneses, E. Najgebauer, G.G. Marleau, M. Therrien, N. Khoury, M. Lynch, G. Yee, S. Baum, K. Florence, S. Ismail, B.W. King, R. Martins, C. Petrescu, C. Li, S. Nadarajah, N. Chan, M. Csanadi, C. Leung, W. Liang, J. Jacobs, I. Mcleod, P. Patel, Y. Gonzales, C. Levesque, L. Trepanier, G. Roederer, R. Ruest, M. Murray, D. Ciricillo, F. Kuhn, A. Gauthier, G. Marleau, R. Stachula, P.L. Tham, R. Genge, J. Fung, M. Grunebaum, R. Ling, K. Pazuki, A.J. Pinto, S.M. Wu, J. Jadd, E. Vivoda, W. Evans, J. Patel, J. Breton, E. Gaudreau, R. Racine, L. Theriault, R. Goyer, H. Gilani, A. Gabriel, P. Vardy, P. Yong, T.S. Lo, A.G. Csaharyn, D. Duchesne, G.N. Chang, E. Silver, W.A. Lock, R. Luton, S.J. Lombard, R. Prosser, R. Mansour, S. Szarka, M. Look, J. Bobadilla Martinez, H. Crooks, A. Mikhail, K. Woods, N.A. Abell, A. Bredenkamp, G. Roberts, E.J. Osborne, P. Johannsson, H. Lam Poyuen, A. Desjardins, J-J. Legare, A. Studniberg, M.H. Elahi, D. Neal, J-C. Bouchard, P. Morency, P. Richard, H. Lo, E. Osborne, A. Fernandez, W. Tsuchida, E. Arcia-Bravo, G.K. Campbell, W.K. Kan, R. Sandhu, J. Carter, M.J. Chayer, W. Ke, R.A. Ng-A-Fook, S. Belyavskaya, B. Green, F.S. Shoukralla, T. Singh, J. Eastmure, G. Parlan, G. Antoniadis, W. Buckton, J.H.S. Tam, R. Curridor, S.P. Singh, J. Werier, D. Busque, M. Marchand, S. Major, P. Fournier, K. Lummack, Y. Suh, H. Bienkowski, D. Fay, R. Smith, V. Danescu, V. Nair, M. Pather, N. Gill, E. Luke, S. Wu, T. Yoong, C. Bhabba, P. Cameron, M. Ho, M. Keltz, A. Wells, F.B. Forbes, F. Woo, L. Grenier, M. Houde, W. Black, F. Laverdiere, Y. Bricault, P. Liboiron, A.M. Wasfi, G. Ste-Marie, M. Azzopardi, O. Noronha, S. Bardai, P. Chaudhari, S. Vorster, K. Sutherland, L. Sewchand, D. Toffolo, A. Patel-Christopher, J. Vladars, J. Johnson, J. Conradie, S.Y. Lam, A.M. Rossiter, G. Verbonac, S. Ngui, G. Sandhu, D. Rouse, P.S.K. Chan, P. Fingrut, S. Gottesman, S. Kahane, M. Kim, G. Litner, J. Marmina, S. Langford, U. Meham, C. Sandor, M. Mazhar, T. Luk, F. Brisson, J. Charbonneau, J. Collingwood, S. Athar, A. Wade, J. Gaudreau, J. Roy, S. Lachance, V. Oudar, P. Giannakis, P. Sventek, R. Falardeau, B. Macmillan, M.J. Lau, J. Beecroft, J. Black, S. Sidhu, G. Fitzpatrick, W. Leung, D. Meittinen, S. Belyea, Z. Lakhani, B. Wheeler and N. Varma.

References

  1. 1.
    Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991 Apr; 121 (4 Pt 1): 1244–63PubMedCrossRefGoogle Scholar
  2. 2.
    Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management: what does it mean in practice? Vasc Health Risk Manag 2007; 3(5): 587–603PubMedGoogle Scholar
  3. 3.
    Smith Jr SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007 Mar; 120(3 Suppl. 1): S3–S11PubMedCrossRefGoogle Scholar
  4. 4.
    Lewington S, Clark R, Quizilbash, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903–13PubMedCrossRefGoogle Scholar
  5. 5.
    Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997 Oct; 10 (10 Pt 1): 1097–102PubMedCrossRefGoogle Scholar
  6. 6.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  7. 7.
    Khan NA, Hemmelgarn B, Padwal R, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2. Therapy. Can J Cardiol 2007 May 15; 23(7): 539–50PubMedCrossRefGoogle Scholar
  8. 8.
    Mancia G, De Backer G, Dominiczak, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87PubMedCrossRefGoogle Scholar
  9. 9.
    Sever PS, Poulter NR, Elliott WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006 Jun 13; 113(23): 2754–72; discussion 2773-4PubMedCrossRefGoogle Scholar
  10. 10.
    Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005 Mar 15; 45(6): 813–27PubMedCrossRefGoogle Scholar
  11. 11.
    Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens 2005 Apr; 23(1) Suppl.: S9–17CrossRefGoogle Scholar
  12. 12.
    Volpe M, Savoia C, De Paolis P, et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002 Nov; 13Suppl. 3: S173–8PubMedCrossRefGoogle Scholar
  13. 13.
    Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther 2004 May–Jun; 11(3): 199–205PubMedCrossRefGoogle Scholar
  14. 14.
    Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004 Jan; 6(1): 10–7CrossRefGoogle Scholar
  15. 15.
    Poggi L, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994; 10Suppl. D: 21D–4DPubMedGoogle Scholar
  16. 16.
    MacMahon S, Neal B, Tzourio C, et al. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep 29; 358(9287): 1033–41CrossRefGoogle Scholar
  17. 17.
    Cleland JG, Tendera M, Adamus J, et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006 Oct; 27(19): 2338–45PubMedCrossRefGoogle Scholar
  18. 18.
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10–16; 366(9489): 895–906PubMedCrossRefGoogle Scholar
  19. 19.
    Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006 Mar 27; 166(6): 659–66PubMedCrossRefGoogle Scholar
  20. 20.
    Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep 6; 362(9386): 782–8PubMedCrossRefGoogle Scholar
  21. 21.
    Karpov Iu A, Shal’nova SA, Deev AD. Prestarium in patients with arterial hypertension and ischemic heart disease (or risk factors): safe achievement of target blood pressure level (the PREMIERA study) [in Russian]. Kardiologiia 2006; 46(6): 21–7PubMedGoogle Scholar
  22. 22.
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep 8; 370(9590): 829–40PubMedCrossRefGoogle Scholar
  23. 23.
    Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005 Jan; 3(1): 15–29PubMedCrossRefGoogle Scholar
  24. 24.
    Louis WJ, Conway EL, Krum H, et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin Exp Pharmacol Physiol 1992; 19 Suppl.: 55–60CrossRefGoogle Scholar
  25. 25.
    Louis WJ, Workman BS, Conway EL, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992; 20(3): 505–11PubMedCrossRefGoogle Scholar
  26. 26.
    Squire IB, MacFayden RJ, Reid JL, et al. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996 May; 27(5): 657–66PubMedCrossRefGoogle Scholar
  27. 27.
    Harris SB, Capes SE, Lillie D, et al. Canadian Diabetes Association. 2003 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003 Dec; 27Suppl. 2: S1–S152Google Scholar
  28. 28.
    Khan NA, McAlister FA, Lweanczuk RZ, et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II. Therapy. Can J Cardiol 2005 Jun; 21(8): 657–72PubMedGoogle Scholar
  29. 29.
    Hemmelgarn BR, Zarnke KB, Campbell NR, et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part I. Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004 Jan; 20(1): 31–40PubMedGoogle Scholar
  30. 30.
    Cushman WC, Basile J. Achieving blood pressure goals: why aren’t we? J Clin Hypertens (Greenwich) 2006 Dec; 8(12): 865–72CrossRefGoogle Scholar
  31. 31.
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007 Jan; 49(1): 69–75PubMedCrossRefGoogle Scholar
  32. 32.
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 Jan; 43(1): 10–7PubMedCrossRefGoogle Scholar
  33. 33.
    Amar J. Patients with resistant hypertension. J Hypertens 2007 Jun; 25Suppl. 1: S3–6CrossRefGoogle Scholar
  34. 34.
    Weber M. Guidelines for assessing outcomes of antihypertensive treatment. Am J Cardiol 1999 Jul 22; 84(2A): 2K–4KPubMedCrossRefGoogle Scholar
  35. 35.
    Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003 Aug 20; 290(7): 898–904PubMedCrossRefGoogle Scholar
  36. 36.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342(3): 145–53PubMedCrossRefGoogle Scholar
  37. 37.
    Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006 Jun; 7(2): 61–3PubMedCrossRefGoogle Scholar
  38. 38.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 May 1; 358(18): 1887–98PubMedCrossRefGoogle Scholar
  39. 39.
    Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005 Sep 10–16; 366(9489): 907–13PubMedCrossRefGoogle Scholar
  40. 40.
    Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007 May 23 (5): 953-60Google Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Richard Ian Ogilvie
    • 1
  • Sanjiv Anand
    • 2
  • Pierre Roy
    • 3
  • Selwyn De Souza
    • 4
  1. 1.Toronto Western Hospital, Hypertension Unit, Hypertension Clinic/Clinical PharmacologyUniversity of TorontoTorontoCanada
  2. 2.Dr Georges-L. Dumont Regional HospitalMonctonCanada
  3. 3.Le Centre de Santé et de Services Sociaux (CSSS) BeauceBeauceville and University of LavalQuebecCanada
  4. 4.OttawaCanada

Personalised recommendations